Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

被引：0

作者：

Fanale, Michelle A. ^{[1
]}

Wang, Zhiqiang ^{[1
]}

Ma, Wencai ^{[1
]}

Oki, Yasuhiro ^{[1
]}

Hagemeister, Fredrick B. ^{[1
]}

Fayad, Luis E. ^{[1
]}

Fowler, Nathan ^{[1
]}

Romaguera, Jorge E. ^{[1
]}

Shah, Nina ^{[2
]}

Chuang, Hubert H. ^{[3
]}

Lei, Feng ^{[4
]}

Horowitz, Sandra B. ^{[5
]}

Chihara, Dai ^{[1
]}

Wesson, Emily ^{[1
]}

Hutto, Toni Y. ^{[1
]}

Ruben, Charnelle ^{[1
]}

Samaniego, Felipe ^{[1
]}

Muzzafar, Tariq ^{[6
]}

Piekarz, Richard ^{[7
]}

Davis, R. Eric ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Pharm, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[7] NCI, Canc Therapeut Evaluat Program, Bethesda, MD 20892 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas
Fanale, Michelle A.
Hagemeister, Fredrick B.
Fayad, Luis
Oki, Yasuhiro
Fowler, Nathan
Romaguera, Jorge
Shah, Nina
Chuang, Hubert
Feng, Lei
Horowitz, Sandra B.
Wesson, Emily
Hutto, Toni Y.
Muzzafar, Tariq
Samaniego, Felipe
Davis, R. Eric
BLOOD, 2014, 124 (21)
[2] A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas
Strati, Paolo
Oki, Yasuhiro
Fayad, Luis E.
Nastoupil, Loretta
Fowler, Nathan H.
Hagemeister, F. B.
Kwak, Larry W.
Lee, Hun Ju
Wang, Michael
Westin, Jason R.
Ruben, Charnelle
Wesson, Emily
Fanale, Michelle A.
BLOOD, 2017, 130
[3] A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas
Strati, Paolo
Nastoupil, Loretta J.
Davis, Richard E.
Fayad, Luis E.
Fowler, Nathan
Hagemeister, Fredrick B.
Kwak, Larry
Oki, Yasuhiro
Wang, Michael
Westin, Jason
Ruben, Charnelle E.
Wesson, Emily T.
Piekarz, Richard
Fanale, Michelle A.
Lee, Hun Ju
HAEMATOLOGICA, 2020, 105 (01) : E26 - E28
[4] Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
Friedberg, Jonathan W.
Mahadevan, Daruka
Cebula, Erin
Persky, Daniel
Lossos, Izidore
Agarwal, Amit B.
Jung, JungAh
Burack, Richard
Zhou, Xiaofei
Leonard, E. Jane
Fingert, Howard
Danaee, Hadi
Bernstein, Steven H.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (01) : 44 - U122
[5] Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Horwitz, Steven M.
Nirmal, Ajit J.
Rahman, Jahan
Xu, Ran
Drill, Esther
Galasso, Natasha
Ganesan, Nivetha
Davey, Theresa
Hancock, Helen
Perez, Leslie
Maccaro, Catherine
Bahgat, Alexandra
Marzouk, Evan
Cathcart, Elizabeth
Moskowitz, Alison
Noy, Ariela
Kumar, Anita
Jacobsen, Eric
Fisher, David C.
Mehta-Shah, Neha
Kim, Youn H.
Khodadoust, Michael
Kotlov, Nikita
Nikitina, Anastasia
Kudryashova, Olga
Zubareva, Valeria
Zornikova, Ksenia
Shin, Nara
Sorokina, Maria
Degryse, Sandrine
Postovalova, Ekaterina
Bagaev, Aleksander
Hosszu, Kinga
Mcavoy, Devin
Boelens, Jaap J.
Wu, Wenchao
Ciantra, Zoe
Appelt, Jackson W.
Trevisani, Christopher
Amaka, Sam
Weinstock, David M.
Vardhana, Santosha A.
NATURE MEDICINE, 2024, 30 (09) : 2517 - 2527
[6] Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Horwitz, Steven M.
Nirmal, Ajit J.
Rahman, Jahan
Xu, Ran
Drill, Esther
Galasso, Natasha
Ganesan, Nivetha
Davey, Theresa
Hancock, Helen
Perez, Leslie
Maccaro, Catherine
Bahgat, Alexandra
Marzouk, Evan
Cathcart, Elizabeth
Moskowitz, Alison
Noy, Ariela
Kumar, Anita
Jacobsen, Eric
Fisher, David C.
Mehta-Shah, Neha
Kim, Youn H.
Khodadoust, Michael
Kotlov, Nikita
Nikitina, Anastasia
Kudryashova, Olga
Zubareva, Valeria
Zornikova, Ksenia
Shin, Nara
Sorokina, Maria
Degryse, Sandrine
Postovalova, Ekaterina
Bagaev, Aleksander
Hosszu, Kinga
Mcavoy, Devin
Boelens, Jaap J.
Wu, Wenchao
Ciantra, Zoe
Appelt, Jackson W.
Trevisani, Christopher
Amaka, Sam
Weinstock, David M.
Vardhana, Santosha A.
NATURE MEDICINE, 2024, : 3778 - 3778
[7] Metronomic Chemotherapy Is Effective and Well Tolerated in Relapsed/ Refractory Elderly Patients with Aggressive B- and T-Cell Lymphomas
Cox, Maria Christina
Cavalieri, Elena
Bianchi, Maria Paola
Porrini, Raffaele
Naso, Virginia
di Girolamo, Marco
Prosperi, Daniela
di Landro, Francesca
Tafuri, Agostino
BLOOD, 2015, 126 (23)
[8] A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B-and T-Cell Lymphomas
Mehta-Shah, Neha
Moskowitz, Alison J.
Lunning, Matthew A.
Lynch, Peggy
Scheuerman, Mark
Minnal, Veenna
Galasso, Natasha
Kumar, Anita
Gerecitano, John
Zelenetz, Andrew D.
Hamlin, Paul A.
Noy, Ariela
Matasar, Matthew J.
Palomba, Maria Lia
Younes, Anas
Schaffer, Wendy
Grewal, Ravinder
Rademaker, Jurgen
Sauter, Craig S.
Dahi, Parastoo B.
Myskowski, Patricia
Kheterpal, Meenal
Dogan, Ahmet
Pulitzer, Melissa
Lubin, Lakeisha
Tang, Laura
Ganesan, Nivetha
Ni, Ai
Horwitz, Steven M.
BLOOD, 2017, 130
[9] A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas
Mehta-Shah, Neha
Moskowitz, Alison J.
Lunning, Matthew
Lynch, Peggy
Scheuerman, Mark
Kumar, Anita
Gerecitano, John F.
Zelenetz, Andrew D.
Hamlin, Paul A., Jr.
Noy, Ariela
Matasar, Matthew J.
Palomba, M. Lia
Younes, Anas
Schaffer, Wendy
Grewal, Ravinder
Rademaker, Jurgen
Sauter, Craig S.
Dahi, Parastoo B.
Myskowski, Patricia
Kheterpal, Meenal
Dogan, Ahmet
Pulitzer, Melissa
Tang, Laura
Ni, Ai
Horwitz, Steven M.
BLOOD, 2016, 128 (22)
[10] Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
Kelly, Kevin R.
Friedberg, Jonathan W.
Park, Steven I.
McDonagh, Kevin
Hayslip, John
Persky, Daniel
Ruan, Jia
Puvvada, Soham
Rosen, Peter
Iyer, Swaminathan Padmanabhan
Stefanovic, Alexandra
Bernstein, Steven H.
Weitman, Steven
Karnad, Anand
Monohan, Gregory
VanderWalde, Ari
Mena, Raul
Schmelz, Monika
Spier, Catherine
Groshen, Susan
Venkatakrishnan, Karthik
Zhou, Xiaofei
Sheldon-Waniga, Emily
Leonard, E. Jane
Mahadevan, Daruka
CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6150 - 6159

← 1 2 3 4 5 →